Cetrotide250 mcg/vial

Cetrotide is a gonadotropin-releasing hormone (GnRH) antagonist indicated for the following use:

• Established/FDA-approved use: Prevention of a premature luteinizing hormone (LH) surge in women undergoing controlled ovarian stimulation (COS) as part of an assisted reproductive technology (ART) program such as in vitro fertilization (IVF).

Cetrotide is always used as an adjunct to, and concurrently with, exogenous gonadotropin therapy (e.g., follicle-stimulating hormone preparations) during a supervised ovarian stimulation cycle; it is not used as a standalone fertility treatment. There are no other well-established or guideline-supported indications outside assisted reproduction, and off-label use in other endocrine conditions (e.g., experimental use in endometriosis or uterine fibroids) is not routine and is not recommended outside a research setting.

Each single-use vial contains Cetrorelix Acetate equivalent to 0.25 mg or 3 mg of cetrorelix base, supplied as a sterile, white to off-white lyophilized (freeze-dried) powder. The product is presented with an accompanying pre-filled syringe or ampoule of sterile water for injection (diluent) used to reconstitute the powder immediately before subcutaneous injection.

Cetrotide is a synthetic decapeptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. It is used exclusively in fertility clinics as part of controlled ovarian stimulation protocols for assisted reproductive technology (ART), where it prevents the pituitary gland from releasing a premature surge of luteinizing hormone (LH) that could otherwise cause early ovulation and compromise egg retrieval. It is supplied as a lyophilized powder for reconstitution and is administered by subcutaneous injection, typically self-administered by the patient after training or given by a healthcare provider, under close monitoring by a reproductive endocrinologist.

Cetrotide belongs to the therapeutic class of GnRH antagonists, a subgroup of fertility hormones used in assisted reproductive technology (ART).

Cetrorelix Acetate competitively and reversibly binds to gonadotropin-releasing hormone (GnRH) receptors on pituitary gonadotroph cells. By blocking these receptors, it causes a rapid, dose-dependent, and reversible suppression of endogenous GnRH action, which in turn suppresses the secretion of luteinizing hormone (LH) and, to a lesser extent, follicle-stimulating hormone (FSH).

Unlike GnRH agonists, which initially stimulate and then eventually suppress gonadotropin release ("flare-up" then down-regulation), Cetrorelix Acetate produces immediate suppression without an initial flare. This action prevents a premature LH surge during the later stages of a gonadotropin-stimulated ovarian cycle, allowing physicians to control the precise timing of final oocyte maturation (triggered separately with human chorionic gonadotropin, hCG) and subsequent egg retrieval.

Cetrotide powder must be reconstituted immediately before use (see Reconstitution) and injected subcutaneously, generally into the lower abdominal wall around the navel, avoiding the navel itself. Injection sites should be rotated with each dose. Patients may self-inject after appropriate training by a healthcare provider, or a nurse/physician may administer the dose. The injection should be given slowly to minimize local discomfort, and the solution should not be used if it is discolored or contains particulate matter.

No formal drug-drug interaction studies have been conducted with Cetrotide. Because it acts on the hypothalamic-pituitary-gonadal axis, a theoretical interaction exists with other hormonal agents that affect this axis (e.g., other GnRH agonists/antagonists), and such combinations are not used together in practice. Cetrotide is used concurrently with exogenous gonadotropins (e.g., FSH preparations) by design as part of the same stimulation protocol; this is an intended, monitored combination rather than a clinically significant adverse interaction. No clinically significant interactions with other commonly used medications have been established.

The most commonly reported side effects of Cetrotide include:

• Local injection-site reactions (redness, itching, swelling, or mild pain) — usually transient
• Headache
• Nausea
• Abdominal pain or discomfort

Less common but clinically important effects include hypersensitivity reactions, up to and including anaphylaxis (see Precautions and Warnings), and ovarian hyperstimulation syndrome (OHSS), which is a recognized risk of the overall gonadotropin-stimulated ART cycle rather than an effect of Cetrotide itself (see Precautions and Warnings).

Cetrotide is contraindicated in known or suspected pregnancy; it is used only before conception, during the ovarian stimulation phase of an ART cycle, and should be discontinued once pregnancy is confirmed or suspected. It is not indicated for use during breastfeeding, as it is not used outside the fertility treatment cycle and has no approved role during lactation. Any inadvertent exposure during early pregnancy should be discussed promptly with the treating physician.

Hypersensitivity reactions: Allergic reactions, including anaphylaxis, have been reported with Cetrotide, sometimes after the first dose. Patients should be monitored appropriately, especially after their initial injection, and treatment should be available for emergency management of hypersensitivity reactions.

Ovarian hyperstimulation syndrome (OHSS): OHSS is a known risk of controlled ovarian stimulation cycles using gonadotropins; this risk is associated with the concurrent gonadotropin therapy used in the same cycle, not with Cetrotide itself, which is intended to help regulate the cycle. Patients should be monitored per standard ART protocols (hormone levels, ultrasound follicle tracking).

Specialist supervision required: Cetrotide must only be used under the supervision of a physician experienced in fertility treatment, with appropriate monitoring facilities; it is not a self-titrated or standalone medication.

Renal impairment: Use with caution in patients with significant renal impairment, as this population has not been systematically studied (see Use in Special Populations).

Clinical experience with overdose of Cetrotide is limited. In the event of a suspected overdose, the patient should seek immediate medical attention or contact a poison control center/emergency services. There is no specific antidote; management should be supportive and symptomatic, with close monitoring by the treating fertility specialist. Do not attempt home treatment for a suspected overdose.

Store Cetrotide at room temperature (below 30°C), protected from light and moisture, and keep the vial in its outer carton until ready for use. Do not freeze. Once reconstituted, the solution should be used immediately and any unused portion discarded. Keep out of reach of children.

Renal impairment: Not systematically studied in patients with significant renal impairment; use with caution and under close specialist supervision (see Precautions and Warnings).

Hepatic impairment: Limited data are available; use with caution.

Elderly: Not applicable, as Cetrotide is used only in women of reproductive age undergoing ART.

Pediatric population: Not indicated; safety and efficacy have not been established in children (see Pediatric Uses).

Treatment duration depends on the regimen and the individual's response to ovarian stimulation:

• Multiple-dose regimen: Daily dosing typically continues for approximately 5 days or more, from stimulation day 5 or 6 through the day of hCG trigger.
• Single-dose regimen: A single 3 mg dose covers approximately 4 days; if stimulation extends beyond this, daily 0.25 mg doses are added until the hCG trigger day.

Cetrotide is used only for the duration of a single controlled ovarian stimulation cycle, as directed by the treating reproductive endocrinologist, and is stopped once the hCG trigger injection is given.

The lyophilized powder in the Cetrotide vial must be reconstituted immediately before use with the accompanying diluent (sterile water for injection). Gently swirl (do not shake vigorously) until a clear solution forms, avoiding excessive foaming. The reconstituted solution should be inspected visually for particulate matter or discoloration before use and, if satisfactory, drawn up and injected subcutaneously right away; any unused reconstituted solution must be discarded and not stored for later use.

Cetrorelix Acetate belongs to the following drug classes: GnRH (gonadotropin-releasing hormone) antagonists; fertility hormones/agents used in assisted reproductive technology (ART).

Cetrorelix Acetate works by competitively blocking pituitary GnRH receptors, producing immediate and reversible inhibition of LH and FSH release. This prevents the natural mid-cycle LH surge from occurring prematurely while follicles are still being matured with exogenous gonadotropins during an ART cycle.

X

Cetrotide is not indicated for use in infants, children, or adolescents. It is used exclusively in adult women of reproductive age undergoing controlled ovarian stimulation as part of an assisted reproductive technology (ART) program. Safety and efficacy in pediatric populations have not been established, and there is no pediatric dosing recommendation.